Targeted agents in the management of small cell lung cancer - present and future

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Small cell lung cancer (SCLC) is a highly aggressive malignancy and the leading cause of cancer-related mortality globally.
• Despite decades of research, treatment strategies for newly diagnosed, relapsed, or refractory SCLC have yielded minimal improvements in clinical outcomes.
• The 5-year mortality rate for SCLC remains high, underscoring the urgent need for effective therapeutic advancements.

Purpose of the Study:

• To review the current literature on SCLC treatment strategies.
• To explore investigational agents and novel approaches aimed at improving clinical outcomes in SCLC.
• To provide an overview of ongoing research and future directions in SCLC therapy.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies.
• Analysis of investigational agents targeting specific pathways in SCLC.
• Evaluation of emerging therapeutic modalities including immunotherapies and antibody-drug conjugates.

Main Results:

• Numerous targeted therapies, including EGFR-TKIs, BCR-ABL TKIs, mTOR inhibitors, and VEGF inhibitors, have been investigated but have not demonstrated survival advantages.
• Other tested agents include DNA repair inhibitors, immunotherapies, and anti-delta-like protein 3 (DLL3) antibody-drug conjugates.
• The review highlights the limited success of conventional and targeted therapies in significantly improving SCLC patient survival.

Conclusions:

• Current treatment paradigms for SCLC have not translated into substantial survival benefits.
• Further research into novel therapeutic strategies, including immunotherapies and targeted agents like DLL3 inhibitors, is crucial for improving SCLC outcomes.
• The review emphasizes the need for continued investigation into the tumor biology of SCLC to identify more effective treatment targets.